cell chronic lymphocytic leukemia (B-CLL) are diagnosed in
the U.S. each year. It is the largest subset of chronic lymphocytic
leukemia (CLL), the most common form of adult leukemia in the western
world. B-CLL is characterized by the accumulation of functionally immature
cells in the bone marrow, blood, lymph tissue and other organs. Because
these cancerous B cells have a longer than normal life span, they begin to
build up and "crowd out" normal, healthy blood cells and can become fatal.
Symptoms include fatigue, bone pain, night sweats, fevers, and decreased
appetite and weight loss. Bone marrow infiltration leads to a lack of
healthy blood cells, thus causing susceptibility to bleedings and weakening
of the immune system, exposing the patient to a higher risk of infection.
Additional Information About Campath
Campath is indicated as a single agent for the treatment of B-cell
chronic lymphocytic leukemia (B-CLL). Campath has a boxed warning which
includes information on cytopenias, infusion reactions, and infections. The
most commonly reported adverse reactions are infusion reactions (fever,
chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea),
cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and
infections (CMV viremia, CMV infection, other infections). In clinical
trials, the frequency of infusion reactions was highest in the first week
of treatment. Other commonly reported adverse reactions include vomiting,
abdominal pain, insomnia and anxiety. The most commonly reported serious
adverse reactions are cytopenias, infusion reactions, and
immunosuppression/infections.
About Genzyme
One of the world's leading biotechnology companies, Genzyme is
dedicated to making a major positive impact on the lives of people with
serious diseases. Since 1981, the company has grown from a small start-up
to a diversified enterprise with more than 9,500 employees in locations
spanning the globe and 2006 revenues of $3.2 billion
'/>"/>
SOURCE Genzyme Corp. and Bayer HealthCare Pharmaceuticals Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
UW-Madison approves new research institute2.
FDA approves GEs heart-imaging technology3.
Senate approves bill to expand stem cell funding4.
FDA approves advanced digital mammography system5.
Building commission approves Institutes for Discovery6.
UW Board of Regents approves $134 million medical research facility7.
FDA approves Bone Cares Hectorol for treatment of kidney disease8.
New Microarray Labeling Kit for Preparing cDNA Probes9.
Antibodies for Studying NMDA Receptor Protein Expression and
Synapse-Specific Immunolabeling10.
aRNA Synthesis and Labeling for Array Analysis11.
Amino Allyl Labeling for Array Analysis